other material
confidence high
sentiment positive
materiality 0.60
CervoMed says new 50 mg neflamapimod tablet plus FDA removal of exposure limit enables 100 mg BID dosing
CervoMed Inc.
- New 50 mg tablet uses most stable crystalline form, addressing manufacturing variability of the 40 mg capsule in Phase 2b RewinD-LB; Phase 1 food-effect/drug-exposure study met primary objectives.
- 50 mg tablet vs prior 40 mg capsule: similar overall plasma exposure, ~20% lower Cmax and ~20% higher 12-hour trough, supporting twice-daily dosing.
- FDA removed neflamapimod's prior plasma exposure limit after a 39-week dog tox study set a NOAEL 3-fold higher than prior dog studies and >30x the active clinical exposure range.
- Plans 100 mg BID regimen; PK modeling projects ~33% higher trough levels than the 40 mg TID dose used in Phase 2a and the Phase 2b extension in DLB, cutting dosing to twice daily.
- CEO John J. Alam says the new tablet addresses the formulation issue from RewinD-LB and expects substantially higher trough concentrations, reducing clinical execution and CMC risk.